Ignyta ASCO update for RXDX-101

11 patients with ALK+ treated (not all NSCLC). 7 patients with ROS1 treated.

Treatment is an oral pill. The previous statement made about the treatment involving an IV infusion was wrong. However the fact that patients only received treatment for 12 days out of a 28 day cycle was correct.

ALK+ NSCLC results so far one partial response (30% shrinkage or better), one prolonged stable response.

ALK+ neuroblastoma (in the brain) one partial response.

http://investor.ignyta.com/releasedetail.cfm?ReleaseID=851598

This entry was posted in Lung cancer, Neuroblastomas, Research, RXDX-101 - entrectinib - by Ignyta. Bookmark the permalink.

Leave a Reply